KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Other Operating Expenses (2016 - 2026)

TherapeuticsMD filings provide 17 years of Other Operating Expenses readings, the most recent being $94000.0 for Q1 2026.

  • On a quarterly basis, Other Operating Expenses fell 48.63% to $94000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $471000.0, a 74.22% decrease, with the full-year FY2025 number at $560000.0, down 68.49% from a year prior.
  • Other Operating Expenses hit $94000.0 in Q1 2026 for TherapeuticsMD, down from $153000.0 in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $143.4 million in Q2 2022 to a low of -$1.4 million in Q1 2022.
  • Median Other Operating Expenses over the past 5 years was $130500.0 (2023), compared with a mean of $11.0 million.
  • Biggest five-year swings in Other Operating Expenses: crashed 105.83% in 2022 and later surged 1025.78% in 2024.
  • TherapeuticsMD's Other Operating Expenses stood at $9.6 million in 2022, then crashed by 94.4% to $537000.0 in 2023, then crashed by 80.07% to $107000.0 in 2024, then skyrocketed by 42.99% to $153000.0 in 2025, then plummeted by 38.56% to $94000.0 in 2026.
  • The last three reported values for Other Operating Expenses were $94000.0 (Q1 2026), $153000.0 (Q4 2025), and $128000.0 (Q3 2025) per Business Quant data.